Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Is AbbVie the Best Dividend King to Buy in September?

It is certainly a good Dividend King to buy in September.

Is AbbVie the Best Dividend King to Buy in September?

Published September 16, 2026 · Category: Finance

Overview

Dividend Kings are arguably among the best income stocks on the planet. These are corporations that have raised their payouts for at least 50 consecutive years. However, members of this elite group aren't all created equal. Some, like Hormel Foods (NYSE: HRL), are going through challenging periods, while others, such as Johnson & Johnson (NYSE: JNJ), are posting solid financial results. AbbVie (NYSE: ABBV), a pharmaceutical giant, is a popular member of this group with a lot going for it. Is this drugmaker the best Dividend King to buy this month? Let's find out.

Image source: The Motley Fool.

AbbVie is a Dividend King by virtue of its legacy as a former division of Abbott Laboratories (NYSE: ABT). Including the time AbbVie spent under the wing of its former parent company, it has increased its payouts for 54 consecutive years. But AbbVie has been impressive in its own right since splitting from Abbott in 2013. AbbVie has grown its dividends at rates similar to Abbott since 2013 and has delivered much better returns over this period.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.